德康醫療 DXCM 深 滬
已收盤 12-05 16:00:00 美东时间
65.49
+0.240
+0.37%
華盛通- 最 高66.75
- 今 開65.38
- 成交量 385.47万股
- 最 低 65.15
- 昨 收 65.25
- 總市值 256.72亿
- 52周最高 93.25
- 市盈率 靜 45.99
- 換手率 0.98%
- 52周最低 54.11
- 委 比 99.54%
- 總股本 3.92亿
- 歷史最高 164.863
- 量 比 0.99
- 振 幅 2.45%
- 歷史最低 1.6875
- 每 手 1
- 風險率 9.04%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 最高500美元！MongoDB获18家大行紧急上调目标价；巴克莱下调理想汽车目标价至18美元
今日重点评级关注：B. Riley证券：维持Seabridge Gold"买入"评级，目标价从50美元升至65美元；HC Wainwright & Co.：维持TRX Gold"买入"评级，目标价从1.2美元升至1.4美元
12-03 09:58
Morgan Stanley Upgrades DexCom to Overweight, Raises Price Target to $75
Morgan Stanley analyst Patrick Wood upgrades DexCom (NASDAQ:DXCM) from Equal-Weight to Overweight and raises the price target from $63 to $75.
12-03 01:34
华尔街顶级分析师最新评级：泰瑞达获上调
华尔街最受关注、且能影响市场走势的研究评级报告现已汇总。以下是由 The Fly 网站整理的今日投资者需关注的评级动态。 五大评级上调案例 斯提夫尔（S...
12-03 00:58
美股大行评级 | 安捷伦科技、Keysight、先科电子获多家大行上调目标价；摩根大通下调亿航智能评级至"中性"，目标价下调至13美元
今日重点评级关注：HC Wainwright & Co.：维持BiomX"买入"评级，目标价从15美元升至26美元；Clear Street：维持Diversified Energy"买入"评级，目标价从23美元升至25美元
11-26 10:07
DexCom Receives FDA Clearance For Its Dexcom Smart Basal Insulin Dosing Optimizer For Patients With Type 2 Diabetes
DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the FDA has cleared Dexcom Smart Basal, the first and only CGM-integrated basal insulin dosing optimizer designed for adults with Type
11-19 21:36
美股大行评级 | 花旗上调英伟达目标价从210美元升至220美元；DraftKings、DoubleVerify遭多家大行下调目标价
今日重点评级关注：Guggenheim：维持InflaRx"买入"评级，目标价从10美元升至22美元；巴克莱：维持Tandem糖尿病护理"超配"评级，目标价从51美元升至55美元
11-11 10:49
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 17:17
Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer
Celldex appointed Teri Lawver as Senior Vice President and Chief Commercial Officer. With over 30 years of experience in the biopharmaceutical and medical device sectors, Lawver succeeds Richard Wright, who is retiring after a decade at Celldex. Lawver's expertise in immunology and inflammation includes successful launches of key treatments, and she will oversee the potential launch of barzolvolimab and advance Celldex's pipeline. Wright's contri...
11-10 13:01
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 10:22
Why TAL Education, Shake Shack And DexCom Just Appeared On Value Investors' Radars
A trio of stocks made an impressive leap in their Benzinga Edge value scores this week, with one standout making a 138% jump.
11-08 22:16
